These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
280 related items for PubMed ID: 15781017
21. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP. Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [Abstract] [Full Text] [Related]
22. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease. Teoh H, Mendelsohn AA, Goodman SG, Jaffer S, Chen RY, Tjia S, Theriault L, Langer A, Leiter LA, Guidelines Based Undertaking for Improvement in Dyslipidemia Related Events (GUIDE) Investigators. Am J Cardiol; 2009 Sep 15; 104(6):798-804. PubMed ID: 19733714 [Abstract] [Full Text] [Related]
23. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin. Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA. Int J Cardiol; 2005 Oct 10; 104(3):338-45. PubMed ID: 16186066 [Abstract] [Full Text] [Related]
24. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Wong ND, Lopez V, Tang S, Williams GR. Am J Cardiol; 2006 Jul 15; 98(2):204-8. PubMed ID: 16828593 [Abstract] [Full Text] [Related]
25. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. Nichols GA, Nag S, Chan W. Am Heart J; 2007 Sep 15; 154(3):554-60. PubMed ID: 17719305 [Abstract] [Full Text] [Related]
26. Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice. Davidson MH, Gandhi SK, Ohsfeldt RL, Fox KM. Am J Med; 2009 Jan 15; 122(1 Suppl):S51-9. PubMed ID: 19110088 [Abstract] [Full Text] [Related]
27. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin. Sampalis JS, Bissonnette S, Habib R, Boukas S, Ezetrol Add-On Investigators. Ann Pharmacother; 2007 Sep 15; 41(9):1345-51. PubMed ID: 17666579 [Abstract] [Full Text] [Related]
28. Prevention of coronary heart disease in primary medical care in Poland: results from the LIPIDOGRAM study. Tomasik T, Jozwiak J, Windak A, Rygiel K, Mastej M, Smithson WH, Mathers N, Tomaszewski M, Kaess BM, Tykarski A, Konduracka E, Grzeszczak W, Lukas W. Eur J Cardiovasc Prev Rehabil; 2011 Apr 15; 18(2):287-96. PubMed ID: 21450675 [Abstract] [Full Text] [Related]
30. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T. Clin Ther; 2007 Nov 15; 29(11):2419-32. PubMed ID: 18158082 [Abstract] [Full Text] [Related]
31. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH. Am J Cardiol; 2007 Nov 15; 100(10):1499-501. PubMed ID: 17996508 [Abstract] [Full Text] [Related]
32. Hypercholesterolemia. Is lipid-lowering worthwhile for older patients? Deedwania PC. Geriatrics; 2000 May 15; 55(5):22-8. PubMed ID: 10826262 [Abstract] [Full Text] [Related]
33. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'. Devroey D, Velkeniers B, Duquet W, Betz W. Int J Cardiol; 2005 May 25; 101(2):231-5. PubMed ID: 15882669 [Abstract] [Full Text] [Related]
34. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X. Clin Ther; 2008 Jan 25; 30(1):84-97. PubMed ID: 18343245 [Abstract] [Full Text] [Related]
35. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines. Clearfield M, Downs JR, Lee M, Langendorfer A, McConathy W, Gotto AM. Am J Cardiol; 2005 Dec 15; 96(12):1674-80. PubMed ID: 16360356 [Abstract] [Full Text] [Related]
36. [Lipid control in diabetic patients in Extremadura (Spain)]. Roberto Robles N, Barroso S, Marcos G, Sánchez Muñoz-Torrero JF, Estudio Cofre. Endocrinol Nutr; 2009 Mar 15; 56(3):112-7. PubMed ID: 19627723 [Abstract] [Full Text] [Related]
37. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia. Sorensen SV, Frick KD, Wade A, Simko R, Burge R. Clin Ther; 2009 Apr 15; 31(4):862-79. PubMed ID: 19446159 [Abstract] [Full Text] [Related]